查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1573225

化疗市场：按类型、药物类别、治疗类型、应用、给药途径、最终用户 - 2025-2030 年全球预测

Chemotherapy Market by Type (Alkylating Agents, Anti-Tumor Antibiotics, Antimetabolites), Drug Class (Alkylating Agents, Antimetabolites, Antitumor Antibiotics), Therapy Type, Application, Route of Administration, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年化疗市值为653.9亿美元，预计2024年将达到727.5亿美元，复合年增长率为11.31%，到2030年将达到1384.7亿美元。

化疗是癌症治疗的基石，它使用强效药物来破坏癌细胞并抑制其生长和转移。它的需求源于其靶向快速分裂细胞的能力，对于单独或与手术或放射结合治疗各种类型的癌症至关重要。应用范围延伸至医院、癌症研究中心和诊所，支援白血病、乳癌、肺癌等多种癌症类型。最终用途范围涵盖成人和儿科肿瘤学，证明对患者更友善的製剂和输送系统的投资是合理的，并且是一个创新的成熟领域。

主要市场统计
基准年[2023] 653.9亿美元
预测年份 [2024] 727.5亿美元
预测年份 [2030] 1384.7亿美元
复合年增长率（%） 11.31%

化疗市场主要受到癌症发生率上升、持续药物开发和精准医学进步等因素的影响。对标靶治疗和个人化医疗的日益关注使得能够提供更有效、毒性更小的治疗方案，创造重大的成长机会。然而，市场成长受到严重副作用、高昂治疗成本以及癌细胞出现多重抗药性等限制因素的挑战。此外，行政障碍和严格的监管核准流程增加了市场扩张的复杂性。

创新在于开发新型药物输送系统、生物分解性的奈米载体，以及改进联合治疗提高疗效，同时最大限度地减少副作用。利用人工智慧和机器学习来改进治疗结果的预测模型也可以提高竞争力。製药公司和学术机构之间的合作研究可以在阐明抗药性疾病的分子基础方面取得突破，并为未来的治疗方法形成可行的见解。儘管前进的道路充满希望，但公司必须克服知识产权问题、不断变化的报销格局以及实验治疗的道德考虑等挑战。总体而言，化疗市场的性质使其成为对抗癌症的关键而复杂的领域，既需要灵活地应对技术进步，又需要有远见来预测不断变化的市场动态。

市场动态：揭示快速发展的化疗市场的关键市场洞察

供需的动态交互作用正在改变化疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 更多采用标靶化疗以改善精准治疗效果
    • 扩大新兴经济体的医疗基础设施和癌症治疗的机会
    • 落实政府化疗药物扶持政策及报销制度
    • 药厂与研究机构合作，推动化疗技术创新
  • 市场限制因素
    • 基本化疗药物短缺对医疗机构持续照护的影响
    • 低收入和开发中国家先进化疗方案的可用性有限
  • 市场机会
    • 整合个人化医疗，根据基因图谱和患者特定资料客製化化疗治疗方案
    • 开发更精确、更有效率的针对特定癌症类型的新型化疗药物
    • 扩大支持性护理服务以改善化疗患者的整体生活品质
  • 市场挑战
    • 平衡化疗药物的功效和毒性，以改善患者的治疗效果，同时最大限度地减少副作用
    • 应对影响化疗价格和市场占有率的专利到期和学名药竞争

波特五力：驾驭化疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解化疗市场的外部影响

外部宏观环境因素在塑造化疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解化疗市场的竞争格局

对化疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵化疗市场供应商绩效评估

FPNV定位矩阵是评估化疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，化疗市场的成功之路

化疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 更多采用标靶化疗以改善精准治疗效果
      • 扩大新兴国家的医疗基础设施和癌症治疗的机会
      • 落实政府化疗药物扶持政策及报销制度
      • 透过製药公司和研究机构之间的合作促进创新
    • 抑制因素
      • 基本化疗药物的短缺正在影响医疗机构提供持续护理
      • 在低收入和新兴国家，获得先进化疗方案的机会有限
    • 机会
      • 整合个人化医疗，根据基因图谱和患者特定资料客製化化疗治疗
      • 开发更精确、更有效率的针对特定癌症类型的新型化疗药物
      • 扩大支持性护理服务以改善化疗患者的整体生活品质
    • 任务
      • 平衡化疗药物的功效和毒性，以改善患者的治疗效果，同时最大限度地减少副作用
      • 专利到期和非专利竞争影响药品价格和市场占有率
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章化疗市场：依类型

  • 烷化剂
  • 抗肿瘤抗生素
  • 抗代谢物
  • 皮质类固醇
  • 有丝分裂抑制剂
  • 拓朴异构酶抑制剂

第七章依药物类别分類的化疗市场

  • 烷化剂
    • 磺酸盐
    • 乙烯亚胺
    • 联氨和三嗪
    • 芥子气衍生物
  • 抗代谢物
    • 叶酸拮抗剂
    • 嘌呤拮抗剂
    • 嘧啶拮抗剂
  • 抗肿瘤抗生素
    • 细胞週期蛋白
    • 色霉素
    • 其他的
  • 皮质类固醇
  • 有丝分裂抑制剂
  • 植物生物碱
    • 喜树碱
    • 表鬼臼毒素
    • 紫杉烷
    • 长春花生物碱
  • 拓朴异构酶抑制剂
    • I型拓朴异构酶抑制剂
    • 拓朴异构酶 II 抑制剂

第八章依治疗类型化疗市场

  • 联合治疗
  • 强化疗法
  • 诱导治疗
  • 维持治疗
  • 安宁疗护

第九章化疗市场：依应用分类

  • 血癌
  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 卵巢癌
  • 胰臟癌
  • 摄护腺癌

第十章化疗市场：依给药途径

  • 静脉
  • 口服
  • 话题

第十一章化疗市场：依最终用户分类

  • 门诊手术中心
  • 医院
  • 调查机构
  • 专科诊所

第十二章美洲化疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太地区化疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十四章欧洲、中东和非洲化疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C04D9

The Chemotherapy Market was valued at USD 65.39 billion in 2023, expected to reach USD 72.75 billion in 2024, and is projected to grow at a CAGR of 11.31%, to USD 138.47 billion by 2030.

Chemotherapy, a cornerstone of cancer treatment, involves the use of potent drugs to destroy or inhibit the growth and spread of cancer cells. Its necessity arises from its ability to target rapidly dividing cells, making it crucial for treating various cancer types, either alone or in conjunction with surgery and radiation. The application scope extends across hospitals, cancer research centers, and clinics, catering to diverse cancer types, including leukemia, breast cancer, and lung cancer. The end-use scope encompasses both adult and pediatric oncology, warranting investments in more patient-friendly formulations and delivery systems, an area ripe for innovation.

KEY MARKET STATISTICS
Base Year [2023] USD 65.39 billion
Estimated Year [2024] USD 72.75 billion
Forecast Year [2030] USD 138.47 billion
CAGR (%) 11.31%

The chemotherapy market is primarily influenced by factors such as the rising incidence of cancer, ongoing drug development, and advancements in precision medicine. The increasing focus on targeted therapies and personalized medicine presents significant growth opportunities, enabling the delivery of more effective and less toxic treatment options. However, market growth is challenged by limitations like severe side effects, high treatment costs, and the emergence of multidrug resistance in cancer cells. Furthermore, administrative hurdles and stringent regulatory approval processes add layers of complexity to market expansion.

Innovation lies in developing novel drug delivery systems, biodegradable nanocarriers, and improvements in combination therapies to enhance efficacy while minimizing side effects. Leveraging AI and machine learning for better predictive modeling of treatment outcomes can also offer a competitive edge. Collaborations between pharmaceutical companies and academic institutions could spur breakthroughs in understanding the molecular basis of resistance, forming actionable insights to tailor future therapies. Despite the promising avenues, companies must navigate challenges such as intellectual property issues, fluctuating reimbursement landscapes, and the ethical considerations of experimental treatments. Overall, the nature of the chemotherapy market demands both agility in responding to technological advancements and the foresight to anticipate changing market dynamics, positioning it as both a crucial yet complex field in the fight against cancer.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chemotherapy Market

The Chemotherapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising adoption of targeted chemotherapy to improve precision treatment outcomes
    • Expansion of healthcare infrastructure and access to cancer care in emerging economies
    • Implementation of supportive government policies and reimbursement schemes for chemotherapy drugs
    • Collaborations between pharmaceutical companies and research institutes driving innovation in chemotherapy
  • Market Restraints
    • Shortages of essential chemotherapy drugs affecting consistent treatment delivery in healthcare facilities
    • Limited availability of advanced chemotherapy options in low-income and developing countries
  • Market Opportunities
    • Integration of personalized medicine to tailor chemotherapy treatments based on genetic profiles and patient-specific data
    • Development of novel chemotherapy agents targeting specific cancer types with higher precision and efficiency
    • Expansion of supportive care services to improve the overall quality of life for chemotherapy patients
  • Market Challenges
    • Balancing efficacy and toxicity of chemotherapy drugs to enhance patient outcomes while minimizing side effects
    • Navigating patent expirations and generic competition impacting chemotherapy drug pricing and market share

Porter's Five Forces: A Strategic Tool for Navigating the Chemotherapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chemotherapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chemotherapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chemotherapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chemotherapy Market

A detailed market share analysis in the Chemotherapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chemotherapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chemotherapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chemotherapy Market

A strategic analysis of the Chemotherapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chemotherapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Seagen Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Chemotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Alkylating Agents, Anti-Tumor Antibiotics, Antimetabolites, Corticosteroids, Mitotic Inhibitors, and Topoisomerase Inhibitors.
  • Based on Drug Class, market is studied across Alkylating Agents, Antimetabolites, Antitumor Antibiotics, Corticosteroids, Mitotic Inhibitors, Plant Alkaloids, and Topoisomerase Inhibitors. The Alkylating Agents is further studied across Alkyl Sulfonates, Ethylenimines, Hydrazines and Triazines, and Mustard Gas Derivatives. The Antimetabolites is further studied across Folate Antagonists, Purine Antagonists, and Pyrimidine Antagonists. The Antitumor Antibiotics is further studied across Anthracyclines, Chromomycins, and Miscellaneous. The Plant Alkaloids is further studied across Camptothecins, Epipodophyllotoxins, Taxanes, and Vinca Alkaloids. The Topoisomerase Inhibitors is further studied across Topoisomerase I Inhibitors and Topoisomerase II Inhibitors.
  • Based on Therapy Type, market is studied across Combination Therapy, Consolidation Therapy, Induction Therapy, Maintenance Therapy, and Palliative Care.
  • Based on Application, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, and Prostate Cancer.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising adoption of targeted chemotherapy to improve precision treatment outcomes
      • 5.1.1.2. Expansion of healthcare infrastructure and access to cancer care in emerging economies
      • 5.1.1.3. Implementation of supportive government policies and reimbursement schemes for chemotherapy drugs
      • 5.1.1.4. Collaborations between pharmaceutical companies and research institutes driving innovation in chemotherapy
    • 5.1.2. Restraints
      • 5.1.2.1. Shortages of essential chemotherapy drugs affecting consistent treatment delivery in healthcare facilities
      • 5.1.2.2. Limited availability of advanced chemotherapy options in low-income and developing countries
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of personalized medicine to tailor chemotherapy treatments based on genetic profiles and patient-specific data
      • 5.1.3.2. Development of novel chemotherapy agents targeting specific cancer types with higher precision and efficiency
      • 5.1.3.3. Expansion of supportive care services to improve the overall quality of life for chemotherapy patients
    • 5.1.4. Challenges
      • 5.1.4.1. Balancing efficacy and toxicity of chemotherapy drugs to enhance patient outcomes while minimizing side effects
      • 5.1.4.2. Navigating patent expirations and generic competition impacting chemotherapy drug pricing and market share
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chemotherapy Market, by Type

  • 6.1. Introduction
  • 6.2. Alkylating Agents
  • 6.3. Anti-Tumor Antibiotics
  • 6.4. Antimetabolites
  • 6.5. Corticosteroids
  • 6.6. Mitotic Inhibitors
  • 6.7. Topoisomerase Inhibitors

7. Chemotherapy Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Alkylating Agents
    • 7.2.1. Alkyl Sulfonates
    • 7.2.2. Ethylenimines
    • 7.2.3. Hydrazines and Triazines
    • 7.2.4. Mustard Gas Derivatives
  • 7.3. Antimetabolites
    • 7.3.1. Folate Antagonists
    • 7.3.2. Purine Antagonists
    • 7.3.3. Pyrimidine Antagonists
  • 7.4. Antitumor Antibiotics
    • 7.4.1. Anthracyclines
    • 7.4.2. Chromomycins
    • 7.4.3. Miscellaneous
  • 7.5. Corticosteroids
  • 7.6. Mitotic Inhibitors
  • 7.7. Plant Alkaloids
    • 7.7.1. Camptothecins
    • 7.7.2. Epipodophyllotoxins
    • 7.7.3. Taxanes
    • 7.7.4. Vinca Alkaloids
  • 7.8. Topoisomerase Inhibitors
    • 7.8.1. Topoisomerase I Inhibitors
    • 7.8.2. Topoisomerase II Inhibitors

8. Chemotherapy Market, by Therapy Type

  • 8.1. Introduction
  • 8.2. Combination Therapy
  • 8.3. Consolidation Therapy
  • 8.4. Induction Therapy
  • 8.5. Maintenance Therapy
  • 8.6. Palliative Care

9. Chemotherapy Market, by Application

  • 9.1. Introduction
  • 9.2. Blood Cancer
  • 9.3. Breast Cancer
  • 9.4. Colorectal Cancer
  • 9.5. Lung Cancer
  • 9.6. Ovarian Cancer
  • 9.7. Pancreatic Cancer
  • 9.8. Prostate Cancer

10. Chemotherapy Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Intravenous
  • 10.3. Oral
  • 10.4. Topical

11. Chemotherapy Market, by End User

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Hospitals
  • 11.4. Research Institutes
  • 11.5. Specialty Clinics

12. Americas Chemotherapy Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Chemotherapy Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Chemotherapy Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Biogen Inc.
  • 6. Bristol-Myers Squibb Company
  • 7. Celgene Corporation
  • 8. Eli Lilly and Company
  • 9. Genentech, Inc.
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Roche Holding AG
  • 17. Sanofi S.A.
  • 18. Seagen Inc.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CHEMOTHERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CHEMOTHERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHEMOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CHEMOTHERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL CHEMOTHERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. CHEMOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. CHEMOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHEMOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHEMOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHEMOTHERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ANTI-TUMOR ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY MARKET SIZE, BY MITOTIC INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ALKYL SULFONATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ETHYLENIMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY MARKET SIZE, BY HYDRAZINES AND TRIAZINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY MARKET SIZE, BY MUSTARD GAS DERIVATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY MARKET SIZE, BY FOLATE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY MARKET SIZE, BY PURINE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY MARKET SIZE, BY PYRIMIDINE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CHEMOTHERAPY MARKET SIZE, BY CHROMOMYCINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CHEMOTHERAPY MARKET SIZE, BY MISCELLANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CHEMOTHERAPY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CHEMOTHERAPY MARKET SIZE, BY MITOTIC INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CHEMOTHERAPY MARKET SIZE, BY CAMPTOTHECINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CHEMOTHERAPY MARKET SIZE, BY EPIPODOPHYLLOTOXINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TAXANES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CHEMOTHERAPY MARKET SIZE, BY VINCA ALKALOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE I INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE II INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CHEMOTHERAPY MARKET SIZE, BY CONSOLIDATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CHEMOTHERAPY MARKET SIZE, BY INDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CHEMOTHERAPY MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CHEMOTHERAPY MARKET SIZE, BY PALLIATIVE CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL CHEMOTHERAPY MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL CHEMOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL CHEMOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL CHEMOTHERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL CHEMOTHERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL CHEMOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL CHEMOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL CHEMOTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL CHEMOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL CHEMOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL CHEMOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 96. BRAZIL CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. BRAZIL CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. CANADA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. CANADA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. MEXICO CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 225. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. TAIWAN CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. TAIWAN CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 247. TAIWAN CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 248. TAIWAN CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 249. TAIWAN CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. THAILAND CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. THAILAND CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 258. THAILAND CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 259. THAILAND CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 260. THAILAND CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 261. THAILAND CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. VIETNAM CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. VIETNAM CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 269. VIETNAM CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 270. VIETNAM CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 271. VIETNAM CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 272. VIETNAM CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 273. VIETNAM CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 290. DENMARK CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. DENMARK CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 292. DENMARK CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 293. DENMARK CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 294. DENMARK CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 295. DENMARK CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 296. DENMARK CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 297. DENMARK CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. DENMARK CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 299. DENMARK CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. EGYPT CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. EGYPT CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 303. EGYPT CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 304. EGYPT CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 305. EGYPT CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 306. EGYPT CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 307. EGYPT CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 308. EGYPT CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. EGYPT CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. EGYPT CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 311. EGYPT CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. FINLAND CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. FINLAND CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 314. FINLAND CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 315. FINLAND CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 316. FINLAND CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 317. FINLAND CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 318. FINLAND CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 319. FINLAND CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. FINLAND CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 321. FINLAND CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 322. FINLAND CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 323. FRANCE CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 324. FRANCE CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 325. FRANCE CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 326. FRANCE CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 327. FRANCE CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 328. FRANCE CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 329. FRANCE CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 330. FRANCE CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 331. FRANCE CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 332. FRANCE CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 333. FRANCE CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 334. GERMANY CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. GERMANY CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 336. GERMANY CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 337. GERMANY CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 338. GERMANY CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 339. GERMANY CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 340. GERMANY CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 341. GERMANY CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 342. GERMANY CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 343. GERMANY CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 344. GERMANY CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 345. ISRAEL CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 346. ISRAEL CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 347. ISRAEL CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 348. ISRAEL CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 349. ISRAEL CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 350. ISRAEL CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 351. ISRAEL CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 352. ISRAEL CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 353. ISRAEL CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 354. ISRAEL CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 355. ISRAEL CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 356. ITALY CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 357. ITALY CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 358. ITALY CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 359. ITALY CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 360. ITALY CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 361. ITALY CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 362. ITALY CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)

TAB